Trump Administration Unveils Negotiated Prices for 15 High-Cost Medicare Drugs: What It Means for 2027 Part D Costs

What Happened

On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the results of the second round of drug price negotiations under the Inflation Reduction Act's Medicare Drug Price Negotiation Program.

In this cycle, CMS finalized negotiated Maximum Fair Prices (MFPs) for 15 high-cost Part D drugs used to treat:

• Several common cancers
• Type 2 diabetes
• Asthma and chronic lung disease
• Autoimmune conditions
• Obesity and cardiometabolic disease

The new prices will apply in Medicare starting January 1, 2027, after a formal implementation period and plan bids for the 2027 contract year.

According to CMS:

• The 15 selected drugs accounted for about $42.5 billion in gross covered Part D spending between January 1 and December 31, 2024 — roughly 15% of the program's total.
• About 5.3 million Part D enrollees filled at least one prescription for these medications during that period.
• The negotiated prices amount to an estimated 44% reduction in net Medicare spending, or about $12 billion in savings, when applied to 2024 utilization patterns.

Analysis from KFF notes that this second round delivers deeper average savings than the first round of 10 drugs (which is projected to reduce net Medicare spending by about 22%), in part because the 2027 list includes high-cost oncology drugs that previously had relatively small rebates and high net prices.

A Politico report highlights that the Trump Administration is touting these numbers as "$12 billion in federal savings," nearly double the estimated savings from the first batch of negotiated prices.

Why This Matters for Medicare Beneficiaries

Even though these negotiated prices don't start until 2027, they sit on top of a rapidly changing Part D landscape that's already reshaping out-of-pocket (OOP) costs.

Layered on Top of the New Part D Drug Caps

Under the Inflation Reduction Act:

• In 2025, Medicare Part D adds a $2,000 annual cap on out-of-pocket spending for covered prescription drugs.
• In 2026, that cap rises slightly to $2,100, reflecting drug spending growth.

Once you hit that cap in a given year, you pay $0 for covered Part D drugs for the rest of the year.

The new negotiated prices will matter most for:

• People who take one or more of the 25 negotiated drugs regularly, especially cancer therapies and GLP-1s like Ozempic and Wegovy
• Beneficiaries who hit the $2,000–$2,100 cap every year, because lower underlying prices can reduce how quickly they reach that limit and how much Medicare spends overall
• People just below the cap today, who may see their annual spending pulled down enough that they no longer reach catastrophic levels

What Kinds of Drugs Are Affected?

KFF's breakdown notes that the 15 drugs include:

• Cancer drugs such as Ibrance and other oncology agents
• Diabetes and weight-loss GLP-1 medications like Ozempic and Wegovy
• Other chronic disease drugs for heart failure, blood disorders, and autoimmune disease

For many of these drugs, pre-negotiation list prices can be in the thousands of dollars per month, so even a percentage-based coinsurance can be punishing — especially for people on fixed incomes.

How It Fits Into 2026 Medicare Policy Changes

Even though the negotiated prices kick in January 1, 2027, they're part of a multi-year redesign of Medicare drug coverage that starts much earlier.

2025–2026: Part D Redesign and Cost Caps

By 2026, the new Part D standard benefit looks roughly like this:

• Deductible: Up to $615
• Initial coverage: 25% coinsurance until your out-of-pocket spending hits $2,100
• After $2,100: $0 out-of-pocket for covered Part D drugs for the rest of the year

From a beneficiary's point of view, the "floor" of protection is the cap itself (you can't pay more than $2,000 in 2025 or $2,100 in 2026 for covered drugs). But the negotiated prices lower the underlying drug costs, which helps:

• Reduce how quickly people hit the cap
• Lower Medicare's spending and, over time, relieve pressure on Part D premiums
• Potentially moderate future IRMAA surcharges for high-income beneficiaries if program-wide Part D costs grow more slowly

2027: Negotiated Prices Go Live

When the 15 newly negotiated prices become effective in 2027, they combine with:

• The $2,100 cap (or whatever it's adjusted to by then)
• Ongoing policy tweaks to shift more catastrophic-phase liability from Medicare to plans and manufacturers

That means high-spending patients may see lower coinsurance amounts from day one (because the price itself is lower), plus the security of an annual cap if they have extremely expensive prescriptions.

Expert and Industry Reactions

Reactions across the policy world have been mixed — supportive of lower prices, but worried about execution.

Policy Analysts: Big Savings, Big Complexity

KFF's quick take calls the new prices a major expansion of Medicare's negotiating power, noting that average net savings from the second round (44%) are twice as large as in the first round (22%).

At the same time, KFF emphasizes that:

• Negotiations for complex cancer and biologic drugs are inherently contentious
• Future rounds could be shaped by legislative tweaks (like new carve-outs or delays for certain blockbuster drugs)

A STAT "First Opinion" piece warns that pharmacies may be the "canary in the coal mine" for how the program actually works on the ground. The new payment model requires manufacturers to pay a refund to pharmacies for each negotiated drug dispensed — and independent pharmacies worry that delayed or inadequate reimbursements could push them not to stock these drugs at all.

Pharmacies and Part D Plans: Access Concerns

STAT also reports that:

• Independent and long-term care pharmacies fear cash-flow crunches and potential reimbursement shortfalls
• A bipartisan group of lawmakers has already urged HHS to address these concerns
• There's concern that Part D plans might respond by putting negotiated drugs on higher tiers, adding stricter utilization management, or quietly steering patients toward more expensive, higher-rebate alternatives

CMS has issued guidance and built out the Medicare Transaction Facilitator infrastructure to help pharmacies flag cash-flow issues, but experts warn that ongoing monitoring of actual dispensing data will be essential.

Political Framing

Politico notes that Trump's CMS is using the announcement to highlight "$12 billion in savings" and to claim that a tougher negotiating stance delivered deeper discounts than the Biden Administration's first round.

KFF's analysis points out a bipartisan twist: the Trump Administration is effectively continuing and expanding a program created by the Biden Administration, while layering on separate "Most Favored Nation" style voluntary price deals of its own.

The result: both parties are trying to claim credit for lower Medicare drug prices — and future negotiations or legal challenges could still reshape the program.

What Medicare Consumers Should Do Now

Nothing about this announcement requires immediate action from beneficiaries. The new prices don't start until 2027, and the list of negotiated drugs is set at the federal level — you can't "opt in" or "opt out."

But there are smart steps to take now:

1. Understand the 2025–2026 Drug Caps

If you have high drug costs today, focus first on the near-term changes:

• The $2,000 cap in 2025 and $2,100 cap in 2026
• How your current drugs count toward that cap
• Whether enrolling in the Medicare Prescription Payment Plan (which lets you spread costs across the year) makes sense for your cash flow

2. Check Whether You Take One of the Negotiated Drugs

If you're on a high-cost cancer drug, GLP-1, or specialty medication, it's worth:

• Asking your pharmacist or prescriber whether your drug is on the first 10 or second 15 negotiated lists
• Keeping an eye on Annual Notice of Change mailings from your plan in 2026–2027 to see how your formulary tier and copays change
• Planning for the possibility that your 2027 out-of-pocket costs could drop, especially if you've been hitting catastrophic coverage

3. Watch for Pharmacy and Access Issues

Because pharmacies and plans are nervous about the new payment flows, beneficiaries should:

• Report any difficulty filling a prescription for a negotiated drug (for example, a pharmacy refusing to stock it) to your plan and, if needed, to 1-800-MEDICARE
• Keep documentation of denied claims or unusual formulary changes, especially if a drug that should be covered under negotiation is effectively being blocked

If you run into trouble, appeal your plan's decision. The negotiated price program does not give plans permission to stop covering these drugs.

4. Keep an Eye on Politics, but Act Based on Current Law

Future administrations and Congress can try to modify the negotiation program — expanding it, narrowing it, or changing the timelines. But for now:

• The first 10 negotiated drugs are scheduled to take effect in 2026
• The next 15 drugs are scheduled for 2027
• The Part D caps in 2025 and 2026 are already written into law and moving forward

If you want to weigh in, you can submit comments to CMS on related guidance documents or contact your members of Congress about how these changes are affecting you.